Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




BD Diagnostics Collaborate With Bruker to Improve Microbial Identification

By LabMedica International staff writers
Posted on 11 Oct 2010
BD Diagnostics (Sparks, MD, USA) announced an international codevelopment and comarketing collaboration with Bruker Daltonics Inc. More...
(Billerica, MA, USA).

BD Diagnostics is a segment of the Becton, Dickinson and Company (Franklin Lakes, NJ, USA), and Bruker Daltonics is a subsidiary of Bruker Corporation (Billerica, MA, USA). The collaboration will promote an emerging, integrated approach to bacterial and fungal identification and antimicrobial susceptibility testing.

Through this collaboration, identification of microorganisms will be performed with the Bruker MALDI Biotyper, a mass spectrometry-based proteomic "fingerprinting” system specifically configured for rapid identification of bacteria and fungi. BD and Bruker intend to combine the MALDI Biotyper microbial ID system with automated antimicrobial susceptibility testing on the BD Phoenix Microbiology System. The MALDI Biotyper and BD EpiCenter software integration will be further developed to optimize workflows for rapid MALDI Biotyper pathogen identification directly on positive blood cultures from the leading BD BACTEC blood culture system. This rapid blood culture-to-ID workflow is supported by Bruker's new MALDI Sepsitype consumables kit.

Microbial identification and antimicrobial susceptibility testing is the end-point of the major work a microbiology laboratory performs on a daily basis. After culturing and isolating bacteria and fungi from patient specimens, organisms need to be identified and tested to determine which drugs will inhibit or stop their growth. The Bruker MALDI Biotyper allows highly accurate, rapid, and cost-effective identification through a process in which organisms are identified by the unique spectrum of the major proteins and peptides that constitute their makeup.

Frank Laukien, Ph.D., President and CEO of Bruker Corporation, said, "Working with a worldwide leader in microbiology and infectious disease will enable us to further expand the groundbreaking MALDI Biotyper molecular method for microbial identification to its full extent.”

Related Links:

BD Diagnostics
Bruker Daltonics Inc.
Becton, Dickinson and Company
Bruker Corporation



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.